ORR was higher with nivolumab plus ipilimumab versus chemotherapy (63% vs 40%) in patients with tumor PD-L1 ≥ 1% but was comparable between treatment arms for patients with tumor PD-L1 < 1% (36% vs 31%) (Table 4). This evidence concerns the gene CD274 and neoplasm.